Vanags LZ, Tan JTM, Galougahi KK, Schaefer A, Wise SG, Murphy A, Ali ZA, Bursill CA

JACC Basic Transl Sci 2018 Apr;3(2):200-209

PMID: 30062205

Abstract

Even the most advanced drug-eluting stents evoke unresolved issues, including chronic inflammation, late thrombosis, and neoatherosclerosis. This highlights the need for novel strategies that improve stent biocompatibility. Our studies show that apolipoprotein A-I (apoA-I) reduces in-stent restenosis and platelet activation, and enhances endothelialization. These findings have therapeutic implications for improving stent biocompatibility.